Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06370000 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality

Study acronym: REMAIN1
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: 3 to 4v7
  2. Re-verified, no change to tracked fieldsv6
  3. Site contact updatedv5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 15, 2024 to Nov 7, 2024
    • Site details revised
    v4
  5. Start date: Sep 1, 2024 to Nov 15, 2024v3
  6. Start date: Jun 1, 2024 to Sep 1, 2024
    • Primary completion date: Oct 31, 2026 to Jan 31, 2027
    • Study completion date: Oct 31, 2028 to Jan 31, 2029
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Test feasibility of an oral maintenance strategy for transplant eligible AML patients in first CR who are medically underserved or have a disadvantage in the CDC SDOH domains
Trial Details
NCT Number NCT06370000
Lead Sponsor Virginia Commonwealth University
Conditions
(from sponsor)		 Acute Myeloid Leukemia
Related terms Leukemia, Myeloid, Acute
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov